keyword
MENU ▼
Read by QxMD icon Read
search

Guideline for hepatocellular carcinoma

keyword
https://www.readbyqxmd.com/read/28637103/-the-development-of-hepatocellular-carcinoma-in-non-alcoholic-fatty-liver-disease
#1
REVIEW
Oh Sang Kwon, Joon Hwan Kim, Ju Hyun Kim
Non-alcoholic fatty liver disease (NAFLD) may be one of the important causes of cryptogenic hepatocellular carcinoma (HCC). NAFLD-related HCCs (NAFLD-HCCs) have the following clinical features: high body mass index, deranged lipid profiles, diabetes mellitus, hypertension, and metabolic syndrome. Among them, obesity, diabetes mellitus, and high Fe contents in the liver are risk factors of developing HCC in patients with NAFLD. Inflammatory cytokines, adipokines, insulin like growth factor-I, and lipotoxicity are intermingled and may cross react with each other to develop HCC...
June 25, 2017: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/28634515/transarterial-chemoembolization-using-40-%C3%A2%C2%B5m-drug-eluting-beads-for-hepatocellular-carcinoma
#2
Giorgio Greco, Tommaso Cascella, Antonio Facciorusso, Roberto Nani, Rodolfo Lanocita, Carlo Morosi, Marta Vaiani, Giuseppina Calareso, Francesca G Greco, Antonio Ragnanese, Marco A Bongini, Alfonso V Marchianò, Vincenzo Mazzaferro, Carlo Spreafico
AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging...
May 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28628947/meta-analysis-of-determinants-of-survival-following-treatment-of-recurrent-hepatocellular-carcinoma
#3
REVIEW
S Erridge, P H Pucher, S R Markar, G Malietzis, T Athanasiou, A Darzi, M H Sodergren, L R Jiao
BACKGROUND: Intrahepatic recurrence of hepatocellular carcinoma (HCC) following resection is common. However, no current consensus guidelines exist to inform management decisions in these patients. Systematic review and meta-analysis of survival following different treatment modalities may allow improved treatment selection. This review aimed to identify the optimum treatment strategies for HCC recurrence. METHODS: A systematic review, up to September 2016, was conducted in accordance with MOOSE guidelines...
June 19, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28626732/albumin-bilirubin-albi-grade-as-part-of-the-evidence-based-clinical-practice-guideline-for-hcc-of-the-japan-society-of-hepatology-a-comparison-with-the-liver-damage-and-child-pugh-classifications
#4
Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Kunihiko Tsuji, Ei Itobayashi, Kazuya Kariyama, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Hideki Kawasaki, Yoichi Hiasa, Kojiro Michitaka
AIM/BACKGROUND: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. METHODS: We analyzed the medical records of 3,495 Japanese HCC patients admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group)...
June 2017: Liver Cancer
https://www.readbyqxmd.com/read/28620797/asia-pacific-clinical-practice-guidelines-on-the-management-of-hepatocellular-carcinoma-a-2017-update
#5
EDITORIAL
Masao Omata, Ann-Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Sadahisa Ogasawara, Pei-Jer Chen, Cosmas Rinaldi A Lesmana, Laurentius A Lesmana, Rino A Gani, Shuntaro Obi, A Kadir Dokmeci, Shiv Kumar Sarin
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments...
June 15, 2017: Hepatology International
https://www.readbyqxmd.com/read/28619403/practice-knowledge-and-barriers-for-screening-of-hepatocellular-carcinoma-among-high-risk-chinese-patients
#6
Kerui Xu, Shinobu Watanabe-Galloway, Fedja A Rochling, Jianjun Zhang, Paraskevi A Farazi, Hongyan Peng, Hongmei Wang, Jiangtao Luo
BACKGROUND: Hepatocellular carcinoma (HCC) is among the leading causes of cancer deaths in China. Considering its poor prognosis when diagnosed late, Chinese guidelines recommend biannual screening for HCC with abdominal ultrasound and serum α-fetoprotein (AFP) test for high-risk populations. OBJECTIVES: To investigate the practice, knowledge, and self-perceived barriers for HCC screening among high-risk hospital patients in China. METHODS: An interview-based questionnaire was conducted among Chinese patients with chronic hepatitis B and/or chronic hepatitis C infection from outpatient clinics at 2 tertiary medical institutions in Shanghai and Wuhan, China...
March 2017: Annals of Global Health
https://www.readbyqxmd.com/read/28611522/radiological-response-and-inflammation-scores-predict-tumour-recurrence-in-patients-treated-with-transarterial-chemoembolization-before-liver-transplantation
#7
Daniele Nicolini, Andrea Agostini, Roberto Montalti, Federico Mocchegiani, Cinzia Mincarelli, Alessandra Mandolesi, Nicola L Robertson, Roberto Candelari, Andrea Giovagnoni, Marco Vivarelli
AIM: To investigate the prognostic value of the radiological response after transarterial chemoembolization (TACE) and inflammatory markers in patients affected by hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). METHODS: We retrospectively evaluated the preoperative predictors of HCC recurrence in 70 patients treated with conventional (n = 16) or doxorubicin-eluting bead TACE (n = 54) before LT. The patient and tumour characteristics, including the static and dynamic alpha-fetoprotein, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) measurements, were recorded...
May 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28609188/subtraction-images-of-gadoxetic-acid-enhanced-mri-effect-on-the-diagnostic-performance-for-focal-hepatic-lesions-in-patients-at-risk-for-hepatocellular-carcinoma
#8
Sang Hyun Choi, So Yeon Kim, Seung Soo Lee, Ju Hyun Shim, Jae Ho Byun, Seunghee Baek, Moon-Gyu Lee
OBJECTIVE: The purpose of this study is to evaluate the effect of subtraction images of gadoxetic acid-enhanced MRI on the image interpretation of focal hepatic lesions in patients at risk for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: We retrospectively analyzed 255 malignant nodules from 233 patients with chronic hepatitis or liver cirrhosis (187 men and 46 women; mean age, 55.2 years) who underwent preoperative gadoxetic acid-enhanced MRI and surgical resection...
June 13, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28603094/liver-transplantation-in-patients-with-incidental-hepatocellular-carcinoma-cholangiocarcinoma-and-intrahepatic-cholangiocarcinoma-a-single-center-experience
#9
Mohammed Elshamy, Naftali Presser, Abdulrahman Y Hammad, Daniel J Firl, Christopher Coppa, John Fung, Federico N Aucejo
BACKGROUND: Reports of liver transplantation (LT) in patients with mixed hepatocellular carcinoma/cholangiocarcinoma (HCC/CC) and intrahepatic cholangiocarcinoma (ICC) are modest and have been mostly retrospective after pathological categorization in the setting of presumed HCC. Some studies suggest that patients undergoing LT with small and unifocal ICC or mixed HCC/CC can achieve about 40%-60% 5-year post-transplant survival. The study aimed to report our experience in patients undergoing LT with explant pathology revealing HCC/CC and ICC...
June 2017: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/28575014/the-outcomes-and-controversies-of-transplant-tourism-lessons-of-an-11-year-retrospective-cohort-study-from-taiwan
#10
Daniel Fu-Chang Tsai, Shi-Wei Huang, Soren Holm, Yi-Ping Lin, Yu-Kang Chang, Chih-Cheng Hsu
BACKGROUND: Transplant tourism has increased rapidly in the past two decades, accounting for about 10% of world organ transplants. However it is ethically controversial and discouraged by professional guidelines. We conducted this study to investigate the outcomes and trends of overseas kidney and liver transplantation in Taiwan to provide a sound basis for ethical reflection. METHODS AND FINDINGS: The Taiwanese National Health Insurance Research Database was used to identify 2381 domestic and 2518 overseas kidney transplant (KT) recipients from 1998 to 2009 and 1758 domestic and 540 overseas liver transplantation (LT) recipients from 1999 to 2009...
2017: PloS One
https://www.readbyqxmd.com/read/28553196/diagnostic-imaging-of-hepatocellular-carcinoma-a-pictorial-essay
#11
Tomasz K Nowicki, Karolina Markiet, Edyta Szurowska
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, which develops mostly in the setting of chronic liver disease. European Association for the Study of the Liver (EASL) and European Organization for Research and Treatment of Cancer (EORTC) prepared guidelines for screening, follow-up and diagnosis of HCC to facilitate decision making and optimize both diagnostic and therapeutic protocols. The review briefly describes etiology, epidemiology and histopathology of HCC and presents EASL-EORTC guidelines for surveillance and diagnosis of HCC...
May 2017: Current Medical Imaging Reviews
https://www.readbyqxmd.com/read/28550393/interval-magnetic-resonance-imaging-an-alternative-to-guidelines-for-indeterminate-nodules-discovered-in-the-cirrhotic-liver
#12
Eliza W Beal, Joseph F Kearney, Jeffery M Chakedis, A James Hanje, Lanla F Conteh, Sylvester M Black, Kenneth Washburn, Kristin M Dittmar, Timothy M Pawlik, Mary R Dillhoff, Carl R Schmidt
BACKGROUND: Current guidelines for the management of indeterminate nodules discovered on surveillance imaging recommend alternate imaging modality or biopsy. This study evaluates the use of short interval MRI rather than immediate CT or biopsy. METHOD: This retrospective cohort study examines outcomes of 111 patients with indeterminate nodules reviewed by a single institution's Liver Tumor Board 2011-2016. Analysis was focused on outcomes stratified by management decision...
May 26, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28548930/comparison-of-treatment-outcome-between-living-donor-liver-transplantation-and-sorafenib-for-patients-with-hepatocellular-carcinoma-beyond-the-milan-criteria
#13
Yuri Cho, Jeong-Hoon Lee, Dong Hyeon Lee, Eun Ju Cho, Su Jong Yu, Nam-Joon Yi, Kwang-Woong Lee, Yoon Jun Kim, Jung-Hwan Yoon, Kyung-Suk Suh
For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. We recently reported that HCC patients with a low MoRAL (model to predict tumor recurrence after LDLT) score (≤ 314.8) have excellent treatment outcomes after living-donor liver transplantation (LDLT), even though they are beyond the Milan criteria. In the present study, we investigated whether LDLT offers a better treatment outcome than sorafenib for patients with HCC beyond the Milan criteria according to the MoRAL score...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28536660/sorafenib-associated-heart-failure-complicated-by-cardiogenic-shock-after-treatment-of-advanced-stage-hepatocellular-carcinoma-a-clinical-case-discussion
#14
Candace Wu, Kamal Shemisa
Background. Sorafenib, an oral tyrosine kinase inhibitor (TKI), targets multiple tyrosine kinase receptors (TKRs) involved in angiogenesis and tumor growth. Studies suggest that inhibition of TKR impacts cardiomyocyte survival. Inhibition of VEGF signaling interrupts angiogenesis and is associated with the development of hypertension and compensatory hypertrophy. Compensated hypertrophy ultimately leads to heart failure. Case Description. A 76-year-old man with a past medical history of systolic heart failure due to ischemic cardiomyopathy and stage IIIC hepatocellular carcinoma (HCC) presented with symptoms of decompensated heart failure...
2017: Case Reports in Cardiology
https://www.readbyqxmd.com/read/28507924/improved-outcomes-following-hepatocellular-carcinoma-hcc-diagnosis-in-patients-screened-for-hcc-in-a-large-academic-liver-center-versus-patients-identified-in-the-community
#15
Nneoma Okoronkwo, Yucai Wang, Capecomorin Pitchumoni, Baburao Koneru, Nikolaos Pyrsopoulos
Background and Aims: Hepatocellular carcinoma (HCC) is the sixth most commonly occurring cancer worldwide. Knowledge and adherence to HCC surveillance guidelines has been associated with earlier detection. We sought to evaluate characteristics and outcomes following HCC diagnosis in patients screened for HCC in a large academic liver center versus patients diagnosed and referred from the community. Methods: We reviewed the records of patients diagnosed with HCC in the liver center of an academic institution from January 1999 till December 2013...
March 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28482112/a-bayesian-screening-approach-for-hepatocellular-carcinoma-using-multiple-longitudinal-biomarkers
#16
Nabihah Tayob, Francesco Stingo, Kim-Anh Do, Anna S F Lok, Ziding Feng
Advanced hepatocellular carcinoma (HCC) has limited treatment options and poor survival, therefore early detection is critical to improving the survival of patients with HCC. Current guidelines for high-risk patients include ultrasound screenings every six months, but ultrasounds are operator dependent and not sensitive for early HCC. Serum α-Fetoprotein (AFP) is a widely used diagnostic biomarker, but it has limited sensitivity and is not elevated in all HCC cases so, we incorporate a second blood-based biomarker, des'γ carboxy-prothrombin (DCP), that has shown potential as a screening marker for HCC...
May 8, 2017: Biometrics
https://www.readbyqxmd.com/read/28476736/nccn-guidelines-insights-hepatobiliary-cancers-version-1-2017
#17
Al B Benson, Michael I D'Angelica, Daniel E Abbott, Thomas A Abrams, Steven R Alberts, Daniel Anaya Saenz, Chandrakanth Are, Daniel B Brown, Daniel T Chang, Anne M Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andrea Karachristos, R Kate Kelley, Robin Kim, Manisha Palta, James O Park, Vaibhav Sahai, Tracey Schefter, Carl Schmidt, Jason K Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G Gary Tian, Jean-Nicolas Vauthey, Alan P Venook, Andrew X Zhu, Karin G Hoffmann, Susan Darlow
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma...
May 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28473066/acr-appropriateness-criteria-%C3%A2-chronic-liver%C3%A2-disease
#18
Jeanne M Horowitz, Ihab R Kamel, Hina Arif-Tiwari, Sumeet K Asrani, Nicole M Hindman, Harmeet Kaur, Michelle M McNamara, Richard B Noto, Aliya Qayyum, Tasneem Lalani
Because liver fibrosis can be treated, it is important to diagnose liver fibrosis noninvasively and monitor response to treatment. Although ultrasound (grayscale and Doppler) can diagnose cirrhosis, it does so unreliably using morphologic and sonographic features and cannot diagnose the earlier, treatable stages of hepatic fibrosis. Transient elastography, ultrasound elastography with acoustic radiation force impulse, and MR elastography are modalities that can assess for hepatic fibrosis. Although all international organizations recommend ultrasound for screening for hepatocellular carcinoma, ultrasound is particularly limited for identifying hepatocellular carcinoma in patients with obesity, nonalcoholic fatty liver disease, and nodular cirrhotic livers...
May 2017: Journal of the American College of Radiology: JACR
https://www.readbyqxmd.com/read/28468285/immune-tolerant-chronic-hepatitis-b-the-unrecognized-risks
#19
REVIEW
Patrick T F Kennedy, Samuel Litwin, Grace E Dolman, Antonio Bertoletti, William S Mason
Chronic infection with hepatitis B virus (HBV) progresses through multiple phases, including immune tolerant, immune active, immune control, and, in a subset of patients who achieve immune control, reactivation. The first, the immune tolerant phase, is considered to be prolonged in duration but essentially benign in nature, lacking long-term consequences, and thus not recommended for antiviral therapy. This review challenges the notion that the immune tolerant phase is truly benign and considers the possibility that events during this phase may contribute significantly to cirrhosis, hepatocellular carcinoma (HCC), and the premature death of 25% of HBV carriers worldwide...
April 29, 2017: Viruses
https://www.readbyqxmd.com/read/28459036/consensus-statement-on-dose-modifications-of-antidiabetic-agents-in-patients-with-hepatic-impairment
#20
REVIEW
Kalyan Kumar Gangopadhyay, Parminder Singh
Liver disease is an important cause of mortality in type 2 diabetes mellitus (T2DM). It is estimated that diabetes is the most common cause of liver disease in the United States. Virtually, entire spectrum of liver disease is seen in T2DM including abnormal liver enzymes, nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma, and acute liver failure. The treatment of diabetes mellitus (DM) in cirrhotic patients has particular challenges as follows: (1) about half the patients have malnutrition; (2) patients already have advanced liver disease when clinical DM is diagnosed; (3) most of the oral antidiabetic agents (ADAs) are metabolized in the liver; (4) patients often have episodes of hypoglycemia...
March 2017: Indian Journal of Endocrinology and Metabolism
keyword
keyword
70152
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"